MurrayMacintyreLumpkinMD

PubMed

• 2 citations
  Transparency practices at the FDA: A barrier to global health.
  Murray M Lumpkin, Margaret A Hamburg, William B Schultz, Joshua M Sharfstein> ;Science. 2022 Aug 5
• 7 citations
  Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World.
  Douglas S. McNair, Murray Lumpkin, Steven E. Kern, Daniel Hartman> ;Clinical Pharmacology and Therapeutics. 2021 Oct 31
• 2 citations
  The COVID-19 crisis as an opportunity to strengthen global regulatory coordination for sustained enhanced access to diagnostics and therapeutics.
  Uttara Soumyanarayanan, Mimi Choong, James Leong, Murray Lumpkin, Guido Rasi, John H. Skerritt, Silke Vogel, John Lim> ;Clinical and Translational Science. 2021 May 1
• 39 citations
  The case for an HIV cure and how to get there
  Mark Dybul, Timothy Attoye, Solange Baptiste, Peter Cherutich, François Dabis, Steven G. Deeks, Carl W. Dieffenbach, Brian P. Doehle, Maureen M Goodenow, Adam Jiang, D...> ;The Lancet. HIV. 2021 Jan 1
• 24 citations
  Navigating facilitated regulatory pathways during a disease X pandemic
  Shmona Simpson, Ajoy Chakrabarti, David Robinson, Keith Chirgwin, Murray Lumpkin> ;NPJ Vaccines. 2020 Oct 23
• 15 citations
  Coming together to improve access to medicines: The genesis of the East African Community's Medicines Regulatory Harmonization initiative.
  Hiiti Baran Sillo, Aggrey Ambali, Samvel Azatyan, Chimwemwe Chamdimba, Eliangiringa Kaale, Joseph Kabatende, Murray Lumpkin, Jane H. Mashingia, David Mukanga, Bonavent...> ;Plos Medicine. 2020 Aug 12
• 19 citations
  Eight years of the East African Community Medicines Regulatory Harmonization initiative: Implementation, progress, and lessons learned.
  Jane H. Mashingia, Vincent Ahonkhai, Noel Aineplan, Aggrey Ambali, Apollo Angole, Mawien Arik, Samvel Azatyan, Peter Baak, Emmanuel Bamenyekanye, Aimable Bizoza, Chimw...> ;Plos Medicine. 2020 Aug 12
• 7 citations
  Scientific considerations for global drug development.
  Jennifer L. Wilson, Kit Wun Kathy Cheung, Lawrence Lin, Elizabeth A. E. Green, Analía Porrás, Ling Zou, David Mukanga, Paul A. Akpa, Delese Mimi Darko, Rae Yuan, Sheng...> ;Science Translational Medicine. 2020 Jul 29
• 4 citations
  Integrating pharmaceutical systems strengthening in the current global health scenario: Three 'uncomfortable truths'
  Tamara Hafner, Marlon Banda, Jillian Clare Kohler, Zaheer-Ud-Din Babar, Murray Lumpkin, Mojisola Christianah Adeyeye, Emmanuel Nfor, Francis Aboagye-Nyame, Javier Guzman> ;Journal of Pharmaceutical Policy and Practice. 2020 Jun 25
• 8 citations
  Pandemic Best Regulatory Practices: An Urgent Need in the COVID-19 Pandemic.
  Murray Lumpkin, John Lim> ;Clinical Pharmacology and Therapeutics. 2020 Oct 1
• 11 citations
  Global regulatory agility during covid-19 and other health emergencies.
  Tippi K. Mak, John Lim, Prapassorn Thanaphollert, Gugu Mahlangu, Emer Cooke, Murray Lumpkin> ;BMJ. 2020 Apr 27
• 11 citations
  The World Health Organization Prequalification Program and Clinical Pharmacology in 2030.
  Terrence F. Blaschke, Murray Lumpkin, Daniel Hartman> ;Clinical Pharmacology and Therapeutics. 2020 Jan 1
• 1 citations
  Recognizing that Evidence is Made, not Born.
  Robyn Lim, David K Lee, Pierre Sabourin, John Ferguson, Marilyn Metcalf, Meredith Smith, Solange Corriol-Rohou, Hans-Georg Eichler, Murray Lumpkin, Gigi Hirsch, Inhua ...> ;Clinical Pharmacology and Therapeutics. 2019 Apr 1
• 42 citations
  Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems
  Lukas Roth, Daniel Bempong, Joseph B. Babigumira, Shabir Banoo, Emer Cooke, David Jeffreys, Lombe Kasonde, Hubert G. M. Leufkens, John C W Lim, Murray Lumpkin, Gugu Ma...> ;Globalization and Health. 2018 Nov 1
• 6 citations
  The cost of entry: An analysis of pharmaceutical registration fees in low-, middle-, and high-income countries.
  Steven G. Morgan, Brandon Yau, Murray Lumpkin> ;Plos One. 2017 Aug 15
• 4 citations
  Optimized Medical Product Regulation in Mexico: A Win-Win for Public and Economic Health.
  Mikel Andoni Arriola Peñalosa, Ricardo Cavazos Cepeda, Mario Alanis Garza, Murray Lumpkin> ;Therapeutic Innovation & Regulatory Science. 2017 May 5
• 40 citations
  Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
  Vincent Ahonkhai, Samuel F. Martins, Alexandre Portet, Murray Lumpkin, Dan Hartman> ;Plos One. 2016 Nov 16
• 16 citations
  Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities
  Lawrence Liberti, Alasdair Breckenridge, Jarno Hoekman, Hubert G. M. Leufkens, Murray Lumpkin, Neil McAuslane, Pieter Stolk, Kaining Zhi, Lembit Rägo> ;Journal of Public Health Policy. 2016 Aug 1
• 11 citations
  Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation
  Duane Schulthess, Lynn G. Baird, Mark R. Trusheim, Thomas F. Unger, Murray Lumpkin, Anton Hoos, Sarah Garner, Pamela Gavin, Michel Goldman, Nathalie Seigneuret, Magda ...> ;Therapeutic Innovation & Regulatory Science. 2016 May 1
• Advancing the science of medicines regulation: the role of the 21st-century medicines regulator.
  Lumpkin, M. M.,Eichler, H. G.,Breckenridge, A.,Hamburg, M. A.,Lönngren, T.,Woods, K.> ;Clin. Pharmacol. Ther.. 2012 Sep 06
• 1 citations
  The FDA goes global.
  Murray M Lumpkin, Lawrence Bachorik> ;FDA Consumer. 2006 Jan 1
• Global regulatory issues.
  Murray M Lumpkin> ;Clinical Advances in Hematology & Oncology. 2004 Dec 1
• Join now to see all